Study of Candidemia and its Antifungal Susceptibility Profile at the University Hospital of Montevideo, Uruguay.

IF 3.6 3区生物学 Q2 MYCOLOGY

Mycopathologia Pub Date : 2023-12-01 Epub Date: 2023-06-14 DOI:10.1007/s11046-023-00744-y

Mauricio Carbia, Vania Medina, Camila Bustillo, Cecilia Martínez, Maria Pía González, Raquel Ballesté

{"title":"Study of Candidemia and its Antifungal Susceptibility Profile at the University Hospital of Montevideo, Uruguay.","authors":"Mauricio Carbia, Vania Medina, Camila Bustillo, Cecilia Martínez, Maria Pía González, Raquel Ballesté","doi":"10.1007/s11046-023-00744-y","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic candidiasis are high mortality infections caused by yeasts of the genus Candida, affecting patients with numerous risk factors. Nowadays, candidemia produced by \"non-albicans\" species has increased considerably. Timely diagnosis and subsequent treatment substantially improve patients' survival. Our objectives are to study the frequency, distribution, and antifungal susceptibility profiles of candidemia isolates in our hospital. We conducted a descriptive, cross-sectional study. Positive blood cultures were recorded from January 2018 to December 2021. Positive Candida genus blood cultures were selected, classified, and analyzed on their susceptibility profile for amphotericin B, fluconazole and caspofungin using AST-YS08® card for VITEK 2 Compact® to determine minimum inhibitory concentration (MIC) and CLSI M60 2020 2nd Edition to determine breakpoints. 3862 positive blood cultures were obtained, 113 (2.93%) presented growth of Candida spp., corresponding to 58 patients. 55.2% came from the Hospitalization Ward and Emergency Services and 44.8% from the Intensive Care Unit. The species were distributed as follows: Nakaseomyces glabratus (Candida glabrata) (32.74%), Candida albicans (27.43%), Candida parapsilosis (23.01%), Candida tropicalis (7.08%) and others (9.73%). Most species were found to be susceptible to most antifungals, except for C. parapsilosis, presenting 4 isolates with resistance to fluconazole and N. glabratus (C. glabrata), whose clinical susceptibility data remains insufficient to provide accurate breakpoints. The percentage of recorded positive blood cultures of Candida spp. was 2.93%, these results were consistent with those reported at a regional level. A predominance of \"non-albicans\" species was observed. It is essential to know the prevalence, epidemiology, and susceptibility profiles of candidemia in our country, as well as being updated on its subsequent changes, maintaining epidemiological surveillance. This allows professionals to map out early and effective therapeutic strategies, staying alert of possible multi-resistant strains.</p>","PeriodicalId":19017,"journal":{"name":"Mycopathologia","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycopathologia","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s11046-023-00744-y","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Systemic candidiasis are high mortality infections caused by yeasts of the genus Candida, affecting patients with numerous risk factors. Nowadays, candidemia produced by "non-albicans" species has increased considerably. Timely diagnosis and subsequent treatment substantially improve patients' survival. Our objectives are to study the frequency, distribution, and antifungal susceptibility profiles of candidemia isolates in our hospital. We conducted a descriptive, cross-sectional study. Positive blood cultures were recorded from January 2018 to December 2021. Positive Candida genus blood cultures were selected, classified, and analyzed on their susceptibility profile for amphotericin B, fluconazole and caspofungin using AST-YS08® card for VITEK 2 Compact® to determine minimum inhibitory concentration (MIC) and CLSI M60 2020 2nd Edition to determine breakpoints. 3862 positive blood cultures were obtained, 113 (2.93%) presented growth of Candida spp., corresponding to 58 patients. 55.2% came from the Hospitalization Ward and Emergency Services and 44.8% from the Intensive Care Unit. The species were distributed as follows: Nakaseomyces glabratus (Candida glabrata) (32.74%), Candida albicans (27.43%), Candida parapsilosis (23.01%), Candida tropicalis (7.08%) and others (9.73%). Most species were found to be susceptible to most antifungals, except for C. parapsilosis, presenting 4 isolates with resistance to fluconazole and N. glabratus (C. glabrata), whose clinical susceptibility data remains insufficient to provide accurate breakpoints. The percentage of recorded positive blood cultures of Candida spp. was 2.93%, these results were consistent with those reported at a regional level. A predominance of "non-albicans" species was observed. It is essential to know the prevalence, epidemiology, and susceptibility profiles of candidemia in our country, as well as being updated on its subsequent changes, maintaining epidemiological surveillance. This allows professionals to map out early and effective therapeutic strategies, staying alert of possible multi-resistant strains.

Abstract Image

查看原文本刊更多论文

乌拉圭蒙得维的亚大学医院念珠菌及其抗真菌敏感性研究。

全身性念珠菌病是由念珠菌属酵母菌引起的高死亡率感染，影响患者具有许多危险因素。如今，由“非白色念珠菌”物种产生的念珠菌已大大增加。及时的诊断和后续治疗大大提高了患者的生存率。我们的目的是研究本院念珠菌分离株的频率、分布和抗真菌敏感性。我们进行了一项描述性的横断面研究。2018年1月至2021年12月血培养呈阳性。选择阳性念珠菌属血培养物，分类并分析其对两性霉素B、氟康唑和caspofungin的敏感性，使用VITEK 2 Compact®的AST-YS08®卡测定最低抑制浓度(MIC)， CLSI M60 2020第二版测定断点。血培养阳性3862例，念珠菌生长113例(2.93%)，对应患者58例。55.2%来自住院病房和急诊服务，44.8%来自重症监护病房。菌种分布为:光秃中丝酵母菌(32.74%)、白色念珠菌(27.43%)、假丝酵母菌(23.01%)、热带念珠菌(7.08%)和其他(9.73%)。大多数菌种均对大多数抗真菌药物敏感，但有4株菌株对氟康唑耐药，另有4株菌株对glabratus (C. glabrata)耐药，其临床药敏数据尚不足以提供准确的断点。念珠菌血培养阳性检出率为2.93%，与地区报告结果一致。观察到“非白色念珠菌”种的优势。必须了解我国念珠菌的流行病学、流行病学和易感性概况，并及时了解其后续变化，保持流行病学监测。这使专业人员能够制定出早期和有效的治疗策略，对可能的多重耐药菌株保持警惕。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mycopathologia 生物-真菌学

CiteScore

6.80

自引率

3.60%

发文量

审稿时长

3 months

期刊介绍： Mycopathologia is an official journal of the International Union of Microbiological Societies (IUMS). Mycopathologia was founded in 1938 with the mission to ‘diffuse the understanding of fungal diseases in man and animals among mycologists’. Many of the milestones discoveries in the field of medical mycology have been communicated through the pages of this journal. Mycopathologia covers a diverse, interdisciplinary range of topics that is unique in breadth and depth. The journal publishes peer-reviewed, original articles highlighting important developments concerning medically important fungi and fungal diseases. The journal highlights important developments in fungal systematics and taxonomy, laboratory diagnosis of fungal infections, antifungal drugs, clinical presentation and treatment, and epidemiology of fungal diseases globally. Timely opinion articles, mini-reviews, and other communications are usually invited at the discretion of the editorial board. Unique case reports highlighting unprecedented progress in the diagnosis and treatment of fungal infections, are published in every issue of the journal. MycopathologiaIMAGE is another regular feature for a brief clinical report of potential interest to a mixed audience of physicians and laboratory scientists. MycopathologiaGENOME is designed for the rapid publication of new genomes of human and animal pathogenic fungi using a checklist-based, standardized format.